Patterns of failures after surgical resection in olfactory neuroblastoma
- PMID: 30506150
- DOI: 10.1007/s11060-018-03056-0
Patterns of failures after surgical resection in olfactory neuroblastoma
Abstract
Introduction: Patterns of failure in patients with olfactory neuroblastoma (ONB) according to two surgical approaches, craniofacial resection (CFR) and endoscopic surgery (ENDO), have yet to be analyzed.
Methods: We retrospectively reviewed 28 patients with surgically treated ONB between January 1995 and October 2017. Fourteen (50.0%) patients underwent CFR (9 CFR alone, 5 ENDO-assisted CFR) and 14 (50.0%) underwent ENDO. Nineteen (67.9%) patients underwent post-operative radiotherapy (RT).
Results: At a median follow-up of 53.8 months (range 10.4-195.3), the 5-year progression-free survival (PFS) and 10-year overall survival were 37.3% and 57.5%, respectively. Patients with adjuvant RT had a 5-year PFS of 46.7%, whereas those treated with surgery alone had a 5-year PFS of 19.4% (p = 0.01). Locoregional failure (LRF) occurred in ten patients (median 59.6 months after initial diagnosis; range 12.7-59.7). Neck node metastasis occurred in 25.0% (7 of 28). Five patients with ENDO showed LRF and underwent proper subsequent treatments with either surgery or adjuvant RT. Approximately 35.7% patients (five patients) in the CFR group experienced distant metastasis in the intracranial dura region (median 116.4 months after initial diagnosis; range 2.6-142.4). Three of four patients who developed LRF after CFR developed dura-based metastasis.
Conclusions: Both dura-based and neck node metastasis in the delayed phase were distinct patterns of failure in ONB. Patterns of recurrence differed based on surgical approach; dura-based metastases were common after CFR. LRF was the distinct failure pattern in ENDO, but could be successfully salvaged. Treatment outcome was improved considerably with RT following surgical resection.
Keywords: Craniofacial resection; Endoscopy; Head and neck cancer; Olfactory neuroblastoma; Survival.
Similar articles
-
Long-term survival outcomes and recurrence patterns of olfactory neuroblastoma: A 13-year experience at a single institution.Auris Nasus Larynx. 2023 Aug;50(4):550-557. doi: 10.1016/j.anl.2022.12.003. Epub 2022 Dec 30. Auris Nasus Larynx. 2023. PMID: 36588056
-
Patterns of recurrence and disease progression in patients with positive-margin olfactory neuroblastoma following primary resection.J Neurosurg. 2024 Mar 22;141(3):711-719. doi: 10.3171/2024.1.JNS23730. Print 2024 Sep 1. J Neurosurg. 2024. PMID: 38518294
-
Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb.Laryngoscope. 2018 Jun;128(6):1274-1280. doi: 10.1002/lary.26908. Epub 2017 Dec 11. Laryngoscope. 2018. PMID: 29226334
-
Ectopic Primary Olfactory Neuroblastoma: Case Series and Literature Review.World Neurosurg. 2022 Feb;158:e645-e653. doi: 10.1016/j.wneu.2021.11.035. Epub 2021 Nov 14. World Neurosurg. 2022. PMID: 34785363 Review.
-
Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: Series report and literature review.Acta Otorrinolaringol Esp (Engl Ed). 2018 Jul-Aug;69(4):208-213. doi: 10.1016/j.otorri.2017.07.001. Epub 2017 Oct 20. Acta Otorrinolaringol Esp (Engl Ed). 2018. PMID: 29061289 Review. English, Spanish.
Cited by
-
Human Olfaction without Apparent Olfactory Bulbs.Neuron. 2020 Jan 8;105(1):35-45.e5. doi: 10.1016/j.neuron.2019.10.006. Epub 2019 Nov 6. Neuron. 2020. PMID: 31706696 Free PMC article.
-
Endoscopic surgery versus various open approaches in esthesioneuroblastoma: a systematic review of the literature.Front Oncol. 2025 May 28;15:1512771. doi: 10.3389/fonc.2025.1512771. eCollection 2025. Front Oncol. 2025. PMID: 40502638 Free PMC article.
-
Intensity-modulated particle beam radiation therapy in the management of olfactory neuroblastoma.Ann Transl Med. 2020 Aug;8(15):926. doi: 10.21037/atm-19-4790. Ann Transl Med. 2020. PMID: 32953726 Free PMC article.
References
-
- Rimmer J, Lund VJ, Beale T, Wei WI, Howard D (2014) Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol. Laryngoscope 124:1542–1549. https://doi.org/10.1002/lary.24562 - DOI - PubMed
-
- Svane-Knudsen V, Jorgensen KE, Hansen O, Lindgren A, Marker P (1998) Cancer of the nasal cavity and paranasal sinuses: a series of 115 patients. Rhinology 36:12–14 - PubMed
-
- Argiris A, Dutra J, Tseke P, Haines K (2003) Esthesioneuroblastoma: the Northwestern University experience. Laryngoscope 113:155–160. https://doi.org/10.1097/00005537-200301000-00029 - DOI - PubMed
-
- Noh OK, Lee SW, Yoon SM, Kim SB, Kim SY, Kim CJ, Jo KJ, Choi EK, Song SY, Kim JH, Ahn SD (2011) Radiotherapy for esthesioneuroblastoma: is elective nodal irradiation warranted in the multimodality treatment approach? Int J Radiat Oncol Biol Phys 79:443–449. https://doi.org/10.1016/j.ijrobp.2009.10.067 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical